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Background: COPD is an independent risk factor for lung cancer, especially in patients with
mild to moderate disease.
Objective: To determine if performing lung cancer screening in GOLD 1 and 2 COPD patients,
results in reduced lung cancer mortality.
Methods: This study compared patients with mild to moderate COPD from 2 cohorts matched
for age, gender, BMI, FEV1%, pack-yrs history and smoking status. The screening group (SG) had
an annual low dose computed tomography (LDCT). The control group (CG) was prospectively
followed with usual care. Lung cancer incidence and mortality densities were compared be-
tween groups.
Results: From an initial sample of 410 (SG) and 735 (CG) patients we were able to match 333
patients from each group. At the same follow-up time lung cancer incidence density wasistery of Health, Government of Spain) research grant nos. PI070792, RD12/0036/0040, RD12/0036/
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the manuscript.
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Mortality reduction in mild to moderate COPD 7031.79/100 person-years in the SG and 4.14/100 person-years in the CG (p Z 0.004). The most
frequent histological type was adenocarcinoma in both SG and CG (65% and 46%, respectively),
followed by squamous cell carcinoma (25% and 37%, respectively). Eighty percent of lung can-
cers in the SG (16/20) were diagnosed in stage I, and all of CG cancers (35/35) were in stage III
or IV. Mortality incidence density from lung cancer (0.08 vs. 2.48/100 person-years, p < 0.001)
was lower in the SG.
Conclusions: This pilot study in patients with mild to moderate COPD suggests that screening
with LDCT detects lung cancer in early stages, and could decrease lung cancer mortality in that
high risk group. Appropriately designed studies should confirm these important findings.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) and lung
cancer are important causes of death in the world in both
genders.1 Epidemiological studies have suggested that, in
comparison to healthy smokers, individuals with COPD have
a greater risk of developing lung cancer.2e4 Recently, our
group has shown that this risk is highest in patients with
COPD in categories 1 and 2 of the old Global Initiative for
Obstructive Lung Diseases (GOLD) classification.5 Fur-
thermore, among individuals with GOLD 1 and 2 COPD, the
risk is even higher in those with alterations of the diffusing
capacity for carbon monoxide (DLCO), or in those with CT
evidence of emphysema.6,7
Recent reports have demonstrated that screening for
lung cancer in subjects with a smoking history using annual
low dose computed tomography (LDCT) results in early
detection8 and in a significant reduction in mortality.9
However, the population targeted in most trials consisted
of smokers and ex-smokers regardless of whether they had
COPD or not. If smoking history is to be used as the selec-
tion criterion for entry in lung cancer screening programs,
the target population may be excessively large. A previous
case finding study10 suggested that including a spirometry
to identify individuals with airflow obstruction could help
find smokers with the highest risk.
In thisworkwe tested thehypothesis that in comparison to
usual care, a screening program using annual LDCT is effec-
tive in detecting lung cancer and in reducing its mortality in
COPD patients with mild and moderate airflow obstruction.
The present pilot study was designed to compare the inci-
dence density of lung cancer, its stage distribution, and lung
cancer mortality in two prospectively followed cohorts of
patients with GOLD stage 1 and 2 COPD matched for age,
gender, BMI, FEV1%, pack-yrs history and smoking status.Methods
Patient selection
COPD was diagnosed in patients with a history of at least 10
pack-years of cigarette smoking and an FEV1/FVC less than
0.70 after the inhalation of 400 ug of albuterol.11 Patients
were excluded if they had a history of asthma, bron-
chiectasis, tuberculosis or other confounding diseases like
severe congestive heart failure (stage III and IV of the NYHA),
obliterative bronchiolitis or diffuse panbronchiolitis. Atentry time none of the patients had symptoms (hemoptysis,
cough, recent weight loss or chest pain) suggestive of lung
cancer. All participants were clinically stable (free of exac-
erbations for at least 8 weeks) and were receiving standard
medical treatment according to the American Thoracic
Society/European Respiratory Society (ATS/ERS) guide-
lines.12 The human-research review board at all institutions
approved the study and all patients signed an informed
consent.
For this study, patients from two prospectively recruited
cohorts from different observational studies performed in
a single country, were matched by age, gender, BMI, FEV1%,
pack-yrs history and smoking status.
The screening group (SG)
Patients in the SG were selected from a cohort of in-
dividuals participating in a lung cancer screening study
conducted at the Clı´nica Universidad de Navarra, in Pam-
plona, Spain. This lung cancer screening study is part of
a large international multicenter study.8 All consecutive
individuals participating in the screening study from Sep-
tember 2000 to December 2010 who had COPD in categories
1 and 2 of the old GOLD classification were selected.11 The
lung cancer screening protocol consisted of a baseline LDCT
of the chest followed by annual repeat studies. Details of
the protocol have been published previously.13
The control group (CG)
The COPD patients in this group were selected from the
cohort of patients participating in the BODE international
multicenter study.14 In order to maintain homogeneity
among the groups, only those patients recruited into the
BODE cohort from Spain between January 2000 and
December 2010 were selected. All patients were prospec-
tively recruited in 3 pulmonary clinics (Hospital Miguel
Servet, Zaragoza; Clinica Universidad de Navarra, Pam-
plona; and Hospital Nuestra Sra de La Candelaria, Tener-
ife). All individuals attending these pulmonary clinics were
invited to participate in the study. For the purpose of this
study, only patients with COPD in categories 1 and 2 of the
old GOLD classification were included in the analysis.11
Fig. 1 shows the consort diagram explaining the
recruitment process in each group.
Matching method
The matching methodology was as follows. From an initial
sample of 410 patients in the SG and 735 patients in the CG
Figure 1 Consort diagram explaining the recruitment pro-
cess in each group.
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with age  2 yrs, same gender, BMI  2 units, FEV1% of
predicted  3%, pack-yrs history  3 and similar smoking
status. When more than one CG patient matched, we ran-
domly chose the patient to be included in the final sample,
being blind to the rest of the evaluated parameters (lung
cancer diagnosis or lung cancer mortality). This event
happened in only 13 patients (4%).
Low-dose computed tomography
LDCT examinations were performed in a single breath-hold
at end-inspiration. The subjects were studied with a four-
row multislice helical CT scanner (Somatom Volume Zoom;
Siemens, Forchheim, Germany) at a low-dose setting
(120 kVp, 20 mA and 1.25 mm slice thickness) for all stud-
ies. All images were reconstructed using a high spatial
frequency algorithm and displayed at window settings
appropriate for viewing the lung parenchyma (window
width of 1500 HU and window center of 650 HU).
Measurement of clinical and physiological
parameters
Trained personnel obtained the following information
during a personal interview at the time of recruitment:
age, gender and the body mass index (BMI), calculated as
the weight in kilograms divided by height in meters. A
specific questionnaire was used to determine smoking
status (current or former) and smoking history (age at ini-
tiation and discontinuation, as well as intensity). From this
information we calculated the total smoking exposure and
expressed it as pack-years. We also evaluated the presence
of comorbidities by the Charlson comorbidity index where
higher score indicate more co-morbidities.15 Pulmonary
function tests were performed following ATS/ERS
guidelines.12Lung cancer diagnosis and histological type
The time between enrollment and lung cancer diagnosis or
death from that cause was expressed in months. The his-
tological type was obtained by reviewing each patient’s
medical record and the pathology report when this infor-
mation was available.
Cause of death
The cause of death was investigated in all of the patients.
Patients were evaluated after enrollment and were seen
every year for at least two years or until death. The patient
and family were contacted if the patient failed to return for
appointments. Death from any cause was recorded. The in-
vestigators at each site determined the cause of death after
reviewing the medical record and the death certificate.
Statistical analysis
Quantitative data with a normal distribution were expressed
using themean and the standard deviation (SD). Quantitative
data with non normal distribution were described with the
median and the interquartile range (IQR). Qualitative data
were described using relative frequencies. Incidence density
of lung cancer was expressed in person-years in each group
and compared by Poisson regression analysis. To compare
patient’s characteristics between the SG and the CG, vari-
ables with normal distribution were analyzed with an un-
paired t test, variables with non normal distribution with
a U ManneWhitney test, and categorical variables with chi
square tests. KaplaneMeier analysis was used to compare
lung cancer and global mortality between patients in both
study groups. The statistical significance was determined by
the log-rank test. Significant levels for all tests were estab-
lished as a two-tailed p-value0.05. Calculationsweremade
with SPSS version 15.0 Inc. (IBM, Chicago, IL, USA).
Results
Baseline characteristics of the patients included in each
study group are shown in Table 1. Three hundred and thirty
three patients were included in each group (Fig. 1). As
expected for a matched study both groups were similar in
terms of age, gender, BMI, FEV1%, pack-yrs history and
smoking status. Patients from the SG had a slightly higher
Charlson index and a slightly shorter follow up time, than
those from the CG.
During the same follow up period (31 months), 20/333
(6%) in the SG and 20/333 (6%) in the CG developed lung
cancer. Lung cancer incidence rate was 1.79/100 person-
years vs. 4.14/100 person-years, p Z 0.004 in the SG and
CG respectively. In the SG, eleven cases were detected in
the first LDCT (prevalent cases) and 9 during the follow up
period (incident cases), but all cases in the CG were diag-
nosed during the follow up time. As shown in Fig. 2, 80% of
the cancers in the SG (16/20) were diagnosed in TNM
stage I, while all of the cancers in the CG (35/35) were
diagnosed in stages IIIeIV. The most frequent histological
type was adenocarcinoma in both SG and CG (65% and 46%,
Table 1 Baseline characteristics of COPD patients included in each group.
Clinical and physiological characteristics Screening group
n Z 333
Control group
n Z 333
p value
Age in years (SD) 61.8 (9.1) 61.9 (8.7) 0.92
Gender (male%) 86 87 0.56
BMI in kg/m2 (SD) 27.8 (4.3) 27.7 (4.0) 0.57
Pack-years (IQR) 40 (26e60) 40 (30e60) 0.57
Current smoking% 37 42 0.13
Charlson index (IQR)% of scores
(1, 2 and >2)
1(1e2)
56, 22, 22
1(1e1)
88, 7, 5
<0.001
<0.001
FEV1% (SD) 85.0 (13.2) 85.1 (12.5) 0.85
FVC% (SD) 109.7 (15.2) 109.0 (15.2) 0.58
FEV1/FVC% (SD) 62.0 (6.2) 61.6 (76.3) 0.43
Follow up time in months (IQR) 31 (5e67) 56 (28e91) 0.001
Lung cancer incidence density at same
follow-up time (31 months)
1.79/100 person-years 4.14/100 person-years 0.004
Lung cancer death incidence density at
same follow-up time (31 months)
0.08/100 person-years 2.48/100 person-years <0.001
Values with normal distribution are shown with their mean (SD); those with non normal distribution with their median (IQR); categorical
variables with percentages.
Mortality reduction in mild to moderate COPD 705respectively), followed by squamous cell carcinoma (25%
and 37%, respectively).
During the same follow up period of 31 months, there
was 1 death due to lung cancer in the SG and 12 in the CG,
corresponding to mortality incidence densities of 0.08/100
person-years and 2.48/100 person-years, respectively.
Lung cancer mortality curves are shown in Fig. 3. By log
rank test lung cancer mortality was significantly lower in
the SG.
Discussion
The main finding of this pilot study suggests that actively
screening for lung cancer using LDCT in patients with mild
to moderate COPD (old GOLD categories 1 and 2) results inFigure 2 TNM stage% of patients at the time of diagnosis in
each group (SC and CG). SG Z screening group, CG Z control
group.a high rate of diagnosis of lung cancer in early, curable
stages, and in high long-term survival rates. Our data also
suggests that without screening, lung cancer is detected in
more advanced stages and results in many avoidable
deaths. This study supports the incorporation of mild to
moderate COPD patients into lung cancer screening pro-
grams and warrants appropriately designed studies to
confirm the improved survival suggested by this approach.
In the past decade, observational studies have shown
that lung cancer screening in current and former smokers
using annual LDCT is effective in detecting cancers in early
stages8 and that it results in prolonged lung cancer specificFigure 3 Kaplan Meier survival curves for lung cancer mor-
tality in each group.
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demonstrated that it also results in a significant reduction
in mortality from lung cancer.9 These studies have
answered many of the questions that had been raised
regarding lung cancer screening, particularly in relation to
the influence of different biases. However, in all screening
trials conducted so far, age and smoking have been the only
criteria used to select high-risk individuals.
While many, and hopefully successful, efforts are un-
derway to establish epidemiological, biological and genetic
markers of risk,16,17 several epidemiological studies have
suggested that COPD diagnosed by spirometry is associated
with an increased risk of lung cancer.2,3,18 Our group has
recently shown that lung cancer occurs more frequently in
mild to moderate (GOLD 1 and 2) COPD, particularly in in-
dividuals with alterations of the diffusing capacity.5 This
may provide an opportunity for early detection of lung
cancer when the expected COPD-specific survival time is
still long, when smoking cessation may have an impact on
the prognosis of COPD,19 and the risks for surgical compli-
cations is low.
The current study extends the observations previously
reported and expands the findings of the recently published
large CT screening randomized controlled trial.9 The first
finding in our study is that screening seems to be especially
useful in the group of patients with COPD (old GOLD stages
1 and 2). Interestingly, the incidence of lung cancer was not
greater in the screening group compared to the control
group and the distribution of cancers among both groups by
histological types was similar. These data support the
notion that screening with LDCT in patients with COPD does
not lead to overdiagnosis. More importantly, lung cancers
were detected at a significantly earlier stage, and the
mortality over time was significantly lower in the screening
group (Fig. 3). The differences in stage distribution are
quite striking. All but four (80%) of the cancers diagnosed
via screening (SG) were in stage I, whereas 100% of the
tumors in the reference group were diagnosed in advanced
stages (III and IV).
A question that may be raised is why we limited the study
of the impact of lung cancer screening to COPD patients in
GOLD categories 1 and 2. As mentioned before, among COPD
patients, those in GOLD categories 1 and 2, especially those
with associated emphysema,6 have the highest risk for lung
cancer. As Young et al. have shown in a population of
smokers,4 at least 50% of all lung cancers occur in individuals
with COPD in these GOLD categories. Moreover, screening
COPD patients with more severe disease (GOLD 3 and 4) may
reduce cost-effectiveness due to the higher incidence of
other competing causes of death such as respiratory failure
or cardiovascular disease.14 It is also possible that a “survival
bias” might be important in that patients with more severe
COPD are survivors and lack the predisposing factors for the
development of lung cancer.16
The difference in stage at the moment of diagnosis is
also reflected in the cancer specific mortality rates, which
were significantly better in the screening group. All
together, these results strongly suggest that screening for
lung cancer in patients with mild to moderate COPD
seems to be effective, resulting in a high percentage of
diagnosis in early curable stages with significantly improved
mortality.In agreement with others, we believe that spirometry is
a useful tool not only to help detect airflow obstruction
such as in asthma and COPD, but perhaps also in the
implementation of screening for patients at risk for lung
cancer.20 COPD remains underdiagnosed due to the infre-
quent use of spirometry in general practices. The PLATINO
study, in which over 5000 individuals from five South
American cities underwent a spirometry, found that up to
89% of those with COPD had not previously been diagnosed
at the time of the survey.21 The great majority of the in-
dividuals who unknowingly had COPD were in GOLD cate-
gories 1 or 2. Both lung cancer and COPD share cigarette
smoking as their main etiologic factor. In the afore-
mentioned PLATINO study21 only half of the entire COPD
cohort, and 69% of those with a previous diagnosis, had
received medical advice to quit smoking. Perhaps the
addition of spirometry to health programs as a whole would
allow the selection of those smokers who having mild
obstruction would be benefit most from LDCT screening.
This will also provide unique teaching opportunities to
address smoking cessation. In support of this statement is
the fact that investigators of lung cancer screening trials
have found high smoking cessation rates associated with
recruitment into the screening programs.22
There are several limitations to this study. Firstly, the
two cohorts of COPD patients were not recruited as part of
the same study and thus conclusions from the comparisons
are made with caution. The SG was selected from an IELCAP
lung cancer screening program, whereas the CG was
selected from the BODE COPD cohort. However, overall the
cohorts had similar clinical characteristics, are from a sim-
ilar geographic origin (Spain), were both prospectively
recruited, and were followed up during the same time
period. Furthermore, the distribution of histologic types of
lung cancer was similar in both groups. Secondly, a limita-
tion to consider relates to the biases known to occur in
screening trials. Lead-time bias and overdiagnosis have
been suggested to cause improved survival in lung cancer
screening programs. However, the NLST results confirm that
the diagnosis of lung cancer in early stages through
screening with LDCT results in improved mortality, dispel-
ling the notion that these biases play important roles,
except for the fact that lead-time is essential for lung
cancer curability. Finally, the investigators who assigned
causes of death were not blind as to which group the COPD
patients belonged to, although the same criteria were used
throughout.
In summary, this proof of concept study suggests that
screening patients with spirometrically determined mild to
moderate COPD for lung cancer using annual LDCT is
effective in diagnosing lung cancer in early stages, and
could result in improved long-term mortality. Furthermore,
this study supports the incorporation of spirometry to lung
cancer screening programs. Appropriately designed studies
are needed to confirm the importance of these findings.Author contribution
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